Targeting TSC by MTORC1-specific BI-steric inhibitors

Ended Project Grant Awarded Last action

Award ID
W81XWH2210547
Recipient
Awarding agency
Obligated
$1,715,894

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $857,947.00 Federal
  • $857,947.00 Non-federal
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors.

The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield needs. This award will support Brigham & Women's Hospital's efforts to investigate new treatments for TSC by developing inhibitors that specifically target the mTORC1 pathway implicated in the disease's pathophysiology. Partners Healthcare System Incorporated is identified as the parent organization of the awardee.

Quick answers

Who received award W81XWH2210547?

W81XWH2210547 was awarded to Brigham & Womens Hospital Inc. by Medical Command (Department of the Army) on August 1, 2022.

How much is award W81XWH2210547 worth?

$1,715,894 has been obligated on W81XWH2210547: $857,947 in federal funding and $857,947 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login